Loading clinical trials...
Loading clinical trials...
A Multicenter, Open-Label, Interventional Study to Evaluate Subject Satisfaction of AbobutulinumtoxinA Treatments in Moderate to Severe Glabellar Lines
Conditions
Interventions
AbobotulinumtoxinA
Locations
6
United States
Galderma Study Site
Los Angeles, California, United States
Galderma Study Site
San Francisco, California, United States
Galderma Study Site
Santa Monica, California, United States
Galderma Study Site
Greenwood Village, Colorado, United States
Galderma Study Site
Chicago, Illinois, United States
Galderma Study Site
Omaha, Nebraska, United States
Start Date
October 2, 2018
Primary Completion Date
November 7, 2019
Completion Date
December 4, 2019
Last Updated
August 26, 2022
NCT05481931
NCT06411002
NCT05146999
NCT05148000
NCT05277337
NCT04249583
Lead Sponsor
Galderma R&D
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions